Correction: Bio-Works receives repeat order worth 2.4 MSEK order for WorkBeads resin

The original press release stated that the order value was 1.9 MSEK, but the actual order value is 2.4 MSEK.

Bio-Works has received a new order from a production customer in the Netherlands worth 2.4 MSEK. The order is a repeat order for a project to which Bio-Works has previously delivered. The customer is a global manufacturer of active pharmaceutical ingredients (APIs) with approximately 1,800 employees.

“We are very happy to have received this repeat order from a customer who we have been working with for many years. The suitability of WorkBeads in large-scale manufacturing is one of the key features of our technology, and this is yet another example of the product’s reliability in process-scale applications,” said Jonathan Royce, CEO at Bio-Works.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail:arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB is appointed Certified Adviser. For more information, visitwww.bio-works.com.

This information is information that Bio-Works Technologies is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-01-18 15:24 CET.